GIPR
Gastric inhibitory polypeptide receptor
As of the edition of 20 October 2026, GIPR (gastric inhibitory polypeptide receptor, UniProt P48546) has 5 drugs tested at it and 4 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P48546
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 14
- Disease areas
- Nutrition and metabolism; Hormones; Urinary and reproductive; Heart and blood vessels; Cancer; Pregnancy and women's health; Digestive system; Immune system
- Registered trials of its drugs
- 237
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 3 |
| Status not established | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tirzepatide | Marketed | Phase 4 | Ends 2039 |
| Retatrutide | Active | Phase 3 | none listed |
| PF-07976016 | Active | Phase 2 | none listed |
| LY3537021 | Active | Phase 2 | none listed |
| KP405 | Status not established | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
The other 3 companies at GIPR
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at GIPR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.